Table 2
SM-AML with t(8;21). Follow up at 20 months, with histological and molecular/cytogenetic findings
| Sample (bone marrow trephine) | AML | Mastocytosis | ||
|---|---|---|---|---|
| Morphological | Cytogenetic t(8;21)* | Morphological | Molecular (c-kit mutation) | |
| *Ratio of AML1-ETO/G6PDH (housekeeping gene); †according to minor World Health Organisation criteria; ‡not sufficient for definite SM diagnosis. | ||||
| AML, acute myeloid leukaemia; NT, not tested; WT, wild type; SM-AHNMD, systemic mastocytosis with haemopoietic clonal non-mast cell lineage disease; +, present; −, absent. | ||||
| 1 (pretherapeutic) | + | 2.47 | +† | + |
| 2 (after induction therapy) | − | 8.25×10−3 | + | No amplification |
| 3 (follow up) | − | 1.01×10−3 | + | + |
| 4 (follow up) | − | 4.98×10−4 | + | + |
| 5 (follow up) | − | 2.11×10−4 | + | No amplification |
| 6 (follow up) | − | 3.57×10−4 | + | WT |
| 7 (follow up) | − | 4.06×10−4 | + | WT |
| 8 (follow up) | − | NT | − | WT |
| 9 (follow up) | − | NT | −/+‡ | + |
